邯郸怀孕多久测出来(邯郸白带 多) (今日更新中)

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

BEIJING, Nov. 28 (Xinhuanet) -- The U.S. FBI and police in the Philippines have arrested four alleged hackers in Manila with connections to a terrorist group in Saudi Arabia, according to media reports Monday.The four who were arrested last Wednesday hacked into AT&T Inc.'s phone systems as part of a plan to funnel money to a Saudi-based terror group, the reports said.The hackers, according to the investigators, worked for a group that helped finance a deadly 2008 terrorist attack in Mumbai, India.Investigators also said the hacking cost AT&T around 2 million U.S. dollars. And an AT&T representative told Reuters that it "ended up writing off some fraudulent charges that appeared on customer bills" but did not comment on the 2 million dollars figure."AT&T and its network were neither targeted nor breached by the hackers," AT&T spokeswoman Jan Rasmussen said. "AT&T only assisted law enforcement in the investigation that led to the arrest of a group of hackers."

SHANGHAI, Jan. 11 (Xinhua) -- The listed arm of China's biggest train maker, China South Locomotive and Rolling Stock Industry (Group) Corporation (CSR), has been allowed by regulatory authorities to raise 9 billion yuan (1.41 billion U.S. dollars) on the stock market, the company said Wednesday.The Hong Kong- and Shanghai- listed CSR Corp. Ltd. will sell 1.96 billion shares at 4.46 yuan apiece to select investors, it said. But CSR's parent -- state-owned CSR Group -- has agreed to buy no less than 6 billion yuan's worth of the shares, leaving the rest to institutional investors.CSR's net profit growth in the third quarter of 2011 plunged to 9.66 percent year-on-year from a high of 85.08 percent in the first half of 2011 as the country put the brakes on development of the railway sector after a deadly bullet train crash on July 23 that killed 40 people and injured 210 others.The decision to slow the development of high-speed rail lines has led to halts in construction of about 90 percent of ongoing railway projects, or 10,000 km of rail lines across the country, local media reported earlier.CSR is the maker of the bullet trains involved in last July's deadly collision. After the accident, the company's executives bought a combined 540,000 share in August, a move seen as an attempt to bolster battered stock prices.Analysts say the fundraising would help CSR greatly ease its financial burdens. The company earlier pledged to maintain profit growth and its dividend policy to boost investors' confidence.

SAN FRANCISCO, Nov. 11 (Xinhua) -- Facebook is close to a settlement with the U.S. Federal Trade Commission (FTC) over the charges that the world's largest social network misled users about its use of their personal information, the U.S. media reported Friday.The proposed settlement would require Facebook to get users' consent before making "material retroactive changes" to its privacy policies, said a report from The Wall Street Journal, citing people familiar with the talks.The agreement with the FTC is also expected to ripple much farther in the tech industry as more companies are developing programs to observe people's online behavior and profiting from the personal information, such as the target advertisements.With a current 800-million-user base worldwide, Facebook changed its user policy in late 2009 to disclose more of users' personal information without adequate notice, leading to a federal investigation along with mounting complaints online.On Thursday, two U.S. representatives asked the Palo Alto, California-based company to explain a February patent application, saying that it raises alarm bells about how the company tracks users on other websites.Outside the U.S., Facebook is also drawing criticism on its privacy policies in countries with strict privacy laws, such as Germany. On Thursday, German authorities said they are considering suing Facebook over its use of facial recognition technology.In a PBS interview aired earlier this week, Facebook's founder and chief executive officer Mark Zuckerberg and chief operating officer Sheryl Sandberg said the company is focused on privacy, addressing that it gives users the ability to protect their privacy.Zuckerberg said Facebook users volunteer all of their personal information on the social network, unlike other Internet giants and advertising networks that compile information "behind your back."

BEIJING, Oct. 7 (Xinhua) -- Chinese scientists are developing new methods like spraying or dropping hepatitis vaccines into people's noses to replace traditional injections, according to a leading expert on immunology.Such researches were sponsored by a key national science project, according to Wen Yumei, an academician of the Chinese Academy of Engineering, also the chairwoman of the 14th International Symposium on Viral Hepatitis and Liver Disease, which is scheduled to be held in Shanghai next July.At a press conference held here Friday for the symposium, experts believed that broad-coverage inoculations is an effective way in facilitating the country's goal in controlling Hepatitis B.China's Ministry of Health has also credited its national immunization program for having protected about 80 million people from being infected with the Hepatitis B virus (HBV) in the 19 years after 1992.Recent report showed that about 93 million Chinese are HBV carriers, accounting for more than a quarter of the world's total.

来源：资阳报